Patricia Pozo-Rosich

Aug 19, 2024 | nature.com | Patricia Pozo-Rosich |Stephen D Silberstein

AbstractOnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has since had a major impact on the well-being of people with chronic migraine.

Oct 5, 2023 | headachejournal.onlinelibrary.wiley.com | Richard Lipton |Patricia Pozo-Rosich |Serena L Orr |Michael Reed

ASC-12 12-item Allodynia Symptom Checklist CaMEO Chronic Migraine Epidemiology and Outcomes CI confidence interval EF Emotional Function EM episodic migraine GAD-7 seven-item Generalized Anxiety Disorder assessment HIT-6 Headache Impact Test-6 HRQoL health-related quality of life ICHD-3 International Classification of Headache Disorders, third edition MHD monthly headache day MSQ Migraine-Specific Quality-of-Life Questionnaire, version 2.1 PHQ-9 Patient Health Questionnaire-9 RFP Role...

Jul 26, 2023 | thelancet.com | Patricia Pozo-Rosich |Universitat Autònoma |Jessica Ailani |Messoud Ashina

Summary In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. We did this randomised, double-blind, placebo-controlled, phase 3 trial at 142 clinical research sites across the USA, the UK, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, and Taiwan.